New Treatments For Patients With Colorectal And Liver Cancer – Part 3 of 3
Goldin’s team found that 40 percent of the 17 patients with shorter intervals – less than three months – since their newest Avastin dose before receiving the microbeads needed their microbead infusion stopped early due to slow blood flow near the tumors, a much higher number than patients whose last Avastin dispense was further in the past. This was expected because the main effect of Avastin is to cut tumors’ blood supply.
Additionally, treatment with Avastin didn’t increase the survival benefit of the microbeads, which added ten to twelve months to patients’ sustenance spans compared to chemotherapy alone, Goldin said – a survival of 34,5 months after the diagnosis of metastatic colon cancer, compared with 24 months. “If you aspect at those survival numbers, there’s a promising benefit” to using microbead radiation. But the cost of both treatments is high – in the tens of thousands of dollars per patient.
Dr Felice Schnoll-Sussman, a gastroenterologist and supervisor of research at the Jay Monahan Center for Gastrointestinal Health at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, said the enquiry won’t change her clinical approach to treating metastatic colon cancer. But “it’s important for us to try to tease through the different treatment recommendations and understand how one treatment affects another. Maybe it helps you get the drift timing, which is never a terrible thing. This is the art of treatment of metastatic colorectal cancer – it’s in the tweaking of the treatments”.